Posted by Michael Wonder on 01 Jun 2022
VBI Vaccines announces UK MHRA marketing authorisation for PreHevbri, a 3 antigen adult hepatitis B vaccine
1 June 2022 - Approval follows the European Commission’s marketing authorisation, granted in April 2022.
VBI Vaccines today announced that the UK MHRA has granted marketing authorisation for PreHevbri [Hepatitis B vaccine (recombinant, adsorbed)] for active immunisation against infection caused by all known subtypes of the hepatitis B virus in adults.
